Kamada Will Supply COVID-19 Treatment to Israel

Israeli biotech Kamada (NASDAQ: KMDA) announced a supply agreement with the Israeli Ministry of Health for its investigational COVID-19 treatment on Monday. The treatment is a hyperimmune immunoglobulin (IgG) product derived from convalescent plasma of volunteers who have recovered from COVID-19. The initial order will be sufficient to treat 500 patients.

In a statement, the company said that this deal "represents the first such contract globally for the supply of a plasma-derived igG product for COVID-19." Kamada's treatment is currently in an ongoing phase 1/2 clinical trial in Israel. Interim results have been positive. According to CEO Amir London, the IgG treatment has "demonstrated a favorable safety profile and showed symptoms improvement in hospitalized, non-ventilated COVID-19 patients with pneumonia ... ."

"Blood Plasma Donation" with map of the world and cartoon image of blood plasma.

Image source: Getty Images.

Kamada is a profitable biotech with $131 million in revenue last year. Its flagship drug is Glassia for patients with emphysema due to hereditary alpha1-antitrypsin (AAT) deficiency. Kamada also has three immunoglobulin products on the market, including one for people who have contracted rabies.

The FDA has recently granted an emergency use authorization for the use of convalescent plasma as a treatment for COVID-19. Many other companies, including Takeda Pharmaceutical and Emergent BioSolutions, are working on plasma-derived therapies.

While many COVID-19 vaccine stocks have skyrocketed this year, the market reaction to COVID-19 treatment stocks has been more muted. That's probably because a successful vaccine might have a market opportunity of a billion people or more. Kamada's plasma therapy is a far smaller niche.

The stock is up 8% on early trading.

10 stocks we like better than Kamada
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Kamada wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More